CarinoDAgostinelliAMolardiA, et al.The role of genetic testing in the prevention of acute aortic dissection. Eur J Prev Cardiol2018; 25(1 Suppl.): 15–23.
2.
VelaRBajonaP. Routine genetic testing for thoracic aortic disease may levy high costs to patients with little benefit. Eur J Prev Cardiol2019; 26: 818–819.
3.
HabashiJPJudgeDPHolmTM, et al.Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science2006; 312: 117–121.
4.
HiratzkaLFBakrisGLBeckmanJA, et al.2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: Executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation2010; 121: 1544–1579.
5.
LacroRVDietzHCSleeperLA, et al.Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med2014; 371: 2061–2071.
6.
FortezaAEvangelistaASanchezV, et al.Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: A randomized clinical trial. Eur Heart J2016; 37: 978–985.
7.
BhattABBuckJSZuflachtJP, et al.Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vasc Med2015; 20: 317–325.
8.
GroeninkMden HartogAWFrankenR, et al.Losartan reduces aortic dilatation rate in adults with Marfan syndrome: A randomized controlled trial. Eur Heart J2013; 34: 3491–3500.
9.
MilleronOArnoultFRopersJ, et al.Marfan Sartan: A randomized, double-blind, placebo-controlled trial. Eur Heart J2015; 36: 2160–2166.
10.
GaoLChenLFanL, et al.The effect of losartan on progressive aortic dilatation in patients with Marfan’s syndrome: A meta-analysis of prospective randomized clinical trials. Int J Cardiol2016; 217: 190–194.
11.
SalvadorGLMarmentiniVMCosmoWR, et al.Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis. Eur J Prev Cardiol2017; 24: 1914–1924.
12.
Fontes-CarvalhoR. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in the treatment of hypertension: Adding more fuel for the fire?Eur J Prev Cardiol2017; 24: 1911–1913.
